Titre : Facteur de croissance endothéliale vasculaire de type A

Facteur de croissance endothéliale vasculaire de type A : Questions médicales fréquentes

Termes MeSH sélectionnés :

Methicillin-Resistant Staphylococcus aureus
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Facteur de croissance endothéliale vasculaire de type A : Questions médicales les plus fréquentes", "headline": "Facteur de croissance endothéliale vasculaire de type A : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Facteur de croissance endothéliale vasculaire de type A : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-02", "dateModified": "2025-02-25", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Facteur de croissance endothéliale vasculaire de type A" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Facteurs de croissance endothéliale vasculaire", "url": "https://questionsmedicales.fr/mesh/D042442", "about": { "@type": "MedicalCondition", "name": "Facteurs de croissance endothéliale vasculaire", "code": { "@type": "MedicalCode", "code": "D042442", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.529.100.800" } } }, "about": { "@type": "MedicalCondition", "name": "Facteur de croissance endothéliale vasculaire de type A", "alternateName": "Vascular Endothelial Growth Factor A", "code": { "@type": "MedicalCode", "code": "D042461", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Krzysztof Gomułka", "url": "https://questionsmedicales.fr/author/Krzysztof%20Gomu%C5%82ka", "affiliation": { "@type": "Organization", "name": "Department of Internal Medicine, Pneumology and Allergology, Wroclaw Medical University, Wroclaw, Poland." } }, { "@type": "Person", "name": "Gilda Varricchi", "url": "https://questionsmedicales.fr/author/Gilda%20Varricchi", "affiliation": { "@type": "Organization", "name": "Department of Translational Medical Sciences, University of Naples Federico II, 80131, Naples, Italy; Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, 80131, Naples, Italy; World Allergy Organization (WAO), Center of Excellence, 80131, Naples, Italy; Institute of Experimental Endocrinology and Oncology \"G. Salvatore\" (IEOS), National Research Council (CNR), 80131, Naples, Italy. Electronic address: gildanet@gmail.com." } }, { "@type": "Person", "name": "Anne Lise Ferrara", "url": "https://questionsmedicales.fr/author/Anne%20Lise%20Ferrara", "affiliation": { "@type": "Organization", "name": "Department of Translational Medical Sciences, University of Naples Federico II, 80131, Naples, Italy; World Allergy Organization (WAO), Center of Excellence, 80131, Naples, Italy; Institute of Experimental Endocrinology and Oncology \"G. Salvatore\" (IEOS), National Research Council (CNR), 80131, Naples, Italy." } }, { "@type": "Person", "name": "Stefania Loffredo", "url": "https://questionsmedicales.fr/author/Stefania%20Loffredo", "affiliation": { "@type": "Organization", "name": "Department of Translational Medical Sciences, University of Naples Federico II, 80131, Naples, Italy; Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, 80131, Naples, Italy; World Allergy Organization (WAO), Center of Excellence, 80131, Naples, Italy; Institute of Experimental Endocrinology and Oncology \"G. Salvatore\" (IEOS), National Research Council (CNR), 80131, Naples, Italy." } }, { "@type": "Person", "name": "Domenico Ribatti", "url": "https://questionsmedicales.fr/author/Domenico%20Ribatti", "affiliation": { "@type": "Organization", "name": "Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Bari, Italy. Electronic address: domenico.ribatti@uniba.it." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "A Nonclassical Mechanism of β-Lactam Resistance in Methicillin-Resistant Staphylococcus aureus and Its Effect on Virulence.", "datePublished": "2022-10-31", "url": "https://questionsmedicales.fr/article/36314912", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1128/spectrum.02284-22" } }, { "@type": "ScholarlyArticle", "name": "Distribution of MecA and Erm Genes among Methicillin-resistant Staphylococcus Aureus with Inducible Resistance to Clindamycin.", "datePublished": "2023-09-08", "url": "https://questionsmedicales.fr/article/37742145", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.33314/jnhrc.v21i1.4337" } }, { "@type": "ScholarlyArticle", "name": "High Prevalence of Multi-drug Resistant Methicillin-Resistant Staphylococcus aureus in Tertiary Egyptian Hospitals.", "datePublished": "2022-05-30", "url": "https://questionsmedicales.fr/article/35656950", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3855/jidc.15833" } }, { "@type": "ScholarlyArticle", "name": "Dissemination of Methicillin-Resistant Staphylococcus aureus Sequence Type 764 Isolates with Mupirocin Resistance in China.", "datePublished": "2023-01-09", "url": "https://questionsmedicales.fr/article/36622214", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1128/spectrum.03794-22" } }, { "@type": "ScholarlyArticle", "name": "Purulent lymphadenitis caused by ST59 community-associated Methicillin-resistant Staphylococcus aureus in an infant.", "datePublished": "2024-05-30", "url": "https://questionsmedicales.fr/article/38865394", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3855/jidc.18798" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Facteurs biologiques", "item": "https://questionsmedicales.fr/mesh/D001685" }, { "@type": "ListItem", "position": 3, "name": "Protéines et peptides de signalisation intercellulaire", "item": "https://questionsmedicales.fr/mesh/D036341" }, { "@type": "ListItem", "position": 4, "name": "Protéines angiogéniques", "item": "https://questionsmedicales.fr/mesh/D042501" }, { "@type": "ListItem", "position": 5, "name": "Facteurs de croissance endothéliale vasculaire", "item": "https://questionsmedicales.fr/mesh/D042442" }, { "@type": "ListItem", "position": 6, "name": "Facteur de croissance endothéliale vasculaire de type A", "item": "https://questionsmedicales.fr/mesh/D042461" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Facteur de croissance endothéliale vasculaire de type A - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Facteur de croissance endothéliale vasculaire de type A", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-19", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Facteur de croissance endothéliale vasculaire de type A", "description": "Comment diagnostiquer une surproduction de VEGF-A ?\nQuels examens sont utilisés pour évaluer le VEGF-A ?\nLe dosage du VEGF-A est-il courant ?\nQuels symptômes peuvent indiquer un problème avec le VEGF-A ?\nLe VEGF-A est-il lié à des maladies spécifiques ?", "url": "https://questionsmedicales.fr/mesh/D042461?mesh_terms=Methicillin-Resistant+Staphylococcus+aureus&page=4#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Facteur de croissance endothéliale vasculaire de type A", "description": "Quels symptômes sont liés à une élévation du VEGF-A ?\nLe VEGF-A peut-il causer des problèmes oculaires ?\nComment le VEGF-A affecte-t-il la circulation sanguine ?\nDes symptômes respiratoires peuvent-ils être liés au VEGF-A ?\nLe VEGF-A est-il impliqué dans des douleurs chroniques ?", "url": "https://questionsmedicales.fr/mesh/D042461?mesh_terms=Methicillin-Resistant+Staphylococcus+aureus&page=4#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Facteur de croissance endothéliale vasculaire de type A", "description": "Peut-on prévenir les maladies liées au VEGF-A ?\nL'alimentation influence-t-elle le VEGF-A ?\nLe tabagisme affecte-t-il le VEGF-A ?\nL'exercice physique peut-il réduire le VEGF-A ?\nLe stress a-t-il un impact sur le VEGF-A ?", "url": "https://questionsmedicales.fr/mesh/D042461?mesh_terms=Methicillin-Resistant+Staphylococcus+aureus&page=4#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Facteur de croissance endothéliale vasculaire de type A", "description": "Quels traitements ciblent le VEGF-A ?\nLe traitement du VEGF-A est-il efficace ?\nY a-t-il des effets secondaires des traitements anti-VEGF ?\nLes thérapies géniques peuvent-elles cibler le VEGF-A ?\nLe VEGF-A peut-il être ciblé par des traitements non médicamenteux ?", "url": "https://questionsmedicales.fr/mesh/D042461?mesh_terms=Methicillin-Resistant+Staphylococcus+aureus&page=4#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Facteur de croissance endothéliale vasculaire de type A", "description": "Quelles complications peuvent survenir avec un excès de VEGF-A ?\nLe VEGF-A est-il lié à des complications rétiniennes ?\nDes complications pulmonaires peuvent-elles être causées par le VEGF-A ?\nLe VEGF-A peut-il aggraver des maladies existantes ?\nComment le VEGF-A influence-t-il la cicatrisation ?", "url": "https://questionsmedicales.fr/mesh/D042461?mesh_terms=Methicillin-Resistant+Staphylococcus+aureus&page=4#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Facteur de croissance endothéliale vasculaire de type A", "description": "Quels sont les facteurs de risque pour une élévation du VEGF-A ?\nL'âge influence-t-il les niveaux de VEGF-A ?\nLe diabète est-il un facteur de risque pour le VEGF-A ?\nLe stress psychologique affecte-t-il le VEGF-A ?\nLes maladies inflammatoires sont-elles liées au VEGF-A ?", "url": "https://questionsmedicales.fr/mesh/D042461?mesh_terms=Methicillin-Resistant+Staphylococcus+aureus&page=4#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une surproduction de VEGF-A ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des biopsies peuvent mesurer les niveaux de VEGF-A." } }, { "@type": "Question", "name": "Quels examens sont utilisés pour évaluer le VEGF-A ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie par résonance magnétique (IRM) et l'échographie peuvent être utilisés." } }, { "@type": "Question", "name": "Le dosage du VEGF-A est-il courant ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il est souvent utilisé dans le suivi des cancers et des maladies vasculaires." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec le VEGF-A ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme des douleurs, des saignements ou des troubles de la vision peuvent survenir." } }, { "@type": "Question", "name": "Le VEGF-A est-il lié à des maladies spécifiques ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il est associé à des maladies comme le cancer, la rétinopathie et l'arthrite." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une élévation du VEGF-A ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent inclure des douleurs, des œdèmes et des troubles circulatoires." } }, { "@type": "Question", "name": "Le VEGF-A peut-il causer des problèmes oculaires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une élévation du VEGF-A peut entraîner des troubles de la vision et des hémorragies rétiniennes." } }, { "@type": "Question", "name": "Comment le VEGF-A affecte-t-il la circulation sanguine ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Il peut provoquer une angiogenèse excessive, entraînant des problèmes vasculaires." } }, { "@type": "Question", "name": "Des symptômes respiratoires peuvent-ils être liés au VEGF-A ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une inflammation pulmonaire peut survenir en raison d'une surproduction de VEGF-A." } }, { "@type": "Question", "name": "Le VEGF-A est-il impliqué dans des douleurs chroniques ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut contribuer à des douleurs chroniques en favorisant l'inflammation." } }, { "@type": "Question", "name": "Peut-on prévenir les maladies liées au VEGF-A ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Adopter un mode de vie sain peut réduire le risque de maladies associées au VEGF-A." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle le VEGF-A ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en antioxydants peut moduler l'expression du VEGF-A." } }, { "@type": "Question", "name": "Le tabagisme affecte-t-il le VEGF-A ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut augmenter les niveaux de VEGF-A et aggraver les maladies vasculaires." } }, { "@type": "Question", "name": "L'exercice physique peut-il réduire le VEGF-A ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut aider à réguler les niveaux de VEGF-A dans le corps." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur le VEGF-A ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut augmenter l'expression du VEGF-A et favoriser l'inflammation." } }, { "@type": "Question", "name": "Quels traitements ciblent le VEGF-A ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les inhibiteurs du VEGF, comme le bevacizumab, sont utilisés pour traiter certains cancers." } }, { "@type": "Question", "name": "Le traitement du VEGF-A est-il efficace ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut réduire la croissance tumorale et améliorer les résultats cliniques." } }, { "@type": "Question", "name": "Y a-t-il des effets secondaires des traitements anti-VEGF ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des effets secondaires comme l'hypertension et des saignements peuvent survenir." } }, { "@type": "Question", "name": "Les thérapies géniques peuvent-elles cibler le VEGF-A ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des approches de thérapie génique sont en cours d'étude pour moduler le VEGF-A." } }, { "@type": "Question", "name": "Le VEGF-A peut-il être ciblé par des traitements non médicamenteux ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des approches comme la radiothérapie peuvent également affecter l'expression du VEGF-A." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec un excès de VEGF-A ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des tumeurs, des hémorragies et des maladies cardiovasculaires peuvent survenir." } }, { "@type": "Question", "name": "Le VEGF-A est-il lié à des complications rétiniennes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une surproduction de VEGF-A peut entraîner des complications comme la néovascularisation." } }, { "@type": "Question", "name": "Des complications pulmonaires peuvent-elles être causées par le VEGF-A ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une élévation du VEGF-A peut contribuer à des maladies pulmonaires comme l'œdème." } }, { "@type": "Question", "name": "Le VEGF-A peut-il aggraver des maladies existantes ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut exacerber des maladies comme le diabète et l'hypertension." } }, { "@type": "Question", "name": "Comment le VEGF-A influence-t-il la cicatrisation ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Un excès de VEGF-A peut perturber la cicatrisation, entraînant des cicatrices anormales." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour une élévation du VEGF-A ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent le tabagisme, l'obésité et des antécédents familiaux de cancer." } }, { "@type": "Question", "name": "L'âge influence-t-il les niveaux de VEGF-A ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les niveaux de VEGF-A peuvent augmenter avec l'âge, augmentant le risque de maladies." } }, { "@type": "Question", "name": "Le diabète est-il un facteur de risque pour le VEGF-A ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le diabète peut augmenter les niveaux de VEGF-A et favoriser des complications vasculaires." } }, { "@type": "Question", "name": "Le stress psychologique affecte-t-il le VEGF-A ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut augmenter l'expression du VEGF-A et aggraver les maladies." } }, { "@type": "Question", "name": "Les maladies inflammatoires sont-elles liées au VEGF-A ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les maladies inflammatoires peuvent augmenter les niveaux de VEGF-A et aggraver les symptômes." } } ] } ] }

Sources (10000 au total)

Distribution of MecA and Erm Genes among Methicillin-resistant Staphylococcus Aureus with Inducible Resistance to Clindamycin.

The emergence of Methicillin-resistant Staphylococcus aureus and its ability to confer cross-resistance to macrolide-lincosamide-streptogramin B has complicated the treatment against it. Gene-based st... S. aureus isolated from different clinical samples was identified by standard microbiological procedures (Gram-staining, colony morphology, and different biochemical tests). Methicillin-resistant and ... Among 120 S. aureus isolates, 51.67% (n=62) were MRSA, and the prevalence of inducibly-resistant, constitutively-resistant and Macrolide-Streptogramin phenotypes were 15.83% (n=19), 28.33% (n=34) and ... Macrolides-Lincosamide-Streptogramin B resistance was predominant among methicillin-resistant S. aureus. While all isolates with inducible clindamycin resistance harbored mecA gene, most of them also ...

High Prevalence of Multi-drug Resistant Methicillin-Resistant Staphylococcus aureus in Tertiary Egyptian Hospitals.

Methicillin-resistant Staphylococcus aureus (MRSA) is an emerging cause of morbidity and mortality worldwide. This work aimed to study the occurrence of multidrug-resistant MRSA (MDR-MRSA) in tertiary... A total of 170 S. aureus isolates were collected from two Egyptian tertiary hospitals in Cairo, between September 2017 and December 2018. MRSA isolates were identified using the conventional microbiol... High prevalence of MRSA isolates was identified (138/170, 81.2%) with 79% of isolates (109/138, 79%) being MDR-MRSA. MRSA isolates were resistant to diverse classes of antimicrobials including β-lacta... MRSA infections remain a noteworthy problem in Egyptian hospitals. MDR-MRSA isolates showed significant genetic diversity indicating the alarmingly high prevalence. Studies should be performed frequen...

Dissemination of Methicillin-Resistant Staphylococcus aureus Sequence Type 764 Isolates with Mupirocin Resistance in China.

Mupirocin, a topical antimicrobial agent, is an important component in the eradication of methicillin-resistant Staphylococcus aureus (MRSA) colonization. The molecular characteristics of 46 mupirocin...

Purulent lymphadenitis caused by ST59 community-associated Methicillin-resistant Staphylococcus aureus in an infant.

Methicillin-resistant Staphylococcus aureus (CA-MRSA), which has the potential to produce serious infections, was a common cause of skin and soft tissue infections, acute purulent lymphadenitis was ra... The patient was a female infant with lumps, tenderness, and fever on the right side of the neck and groin. Laboratory tests suggested a bacterial infection. The diagnosis of acute purulent lymphadenit... 17 days after admission, the patient showed signs of clinical recovery.... The incident brought to light the possible spread of CA-MRSA in the Chinese population. Even without a definite path of infection, CA-MRSA should be taken into consideration when the standard treatmen...

Effects of Phomopsidione on the Viability, Virulence, and Metabolites Profile of Methicillin-Resistant Staphylococcus aureus (MRSA).

Methicillin-resistant Staphylococcus aureus (MRSA) infections have become one of the most threatening multidrug-resistant pathogens. Thus, an ongoing search for anti-MRSA compounds remains an urgent n...

Antibacterial and antibiofilm efficacy of repurposing drug hexestrol against methicillin-resistant Staphylococcus aureus.

There has been an explosion in the prevalence of methicillin-resistant Staphylococcus aureus (MRSA) because of the indiscriminate use of antibiotics. In this study, we repurposed hexestrol (HXS) as an...

Rapid identification of methicillin-resistant Staphylococcus aureus by MALDI-TOF MS: A meta-analysis.

Invasive infections caused by methicillin-resistant Staphylococcus aureus (MRSA) are associated with high mortality and morbidity. The sooner the pathogen is determined, the better it is beneficial to...

Sub-inhibitory concentrations of tetrabromobisphenol A induce the biofilm formation of methicillin-resistant Staphylococcus aureus.

Biofilm formation by methicillin-resistant Staphylococcus aureus (MRSA) on indwelling medical devices complicates the treatment of infection. Tetrabromobisphenol A (TBBPA), a synthetic, lipophilic, ha...

Increased Incidence of Methicillin-Resistant Staphylococcus aureus in Knee and Hip Prosthetic Joint Infection.

Periprosthetic joint infection (PJI) is a devastating complication of knee and hip arthroplasty. Past literature has shown that gram-positive bacteria are commonly responsible for these infections, al... This is a multi-institutional retrospective review of patients who had a knee or hip PJI from 1990 to 2020. Patients with a known causative organism were included and those with insufficient culture s... There was a statistically significant positive linear trend in the incidence of methicillin-resistant Staphylococcus aureus over time (P = .0088) as well as a statistically significant negative linear... The incidence of methicillin-resistant Staphylococcus aureus PJI is increasing over time, whereas, coagulase-negative staphylococci PJI is decreasing, paralleling the global trend of antibiotic resist...